

# **Astigmatism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/AA5ECDD58B6EEN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: AA5ECDD58B6EEN

## **Abstracts**

The 7 major astigmatism markets reached a value of US\$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The astigmatism market has been comprehensively analyzed in IMARC's new report titled "Astigmatism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Astigmatism refers to a common eye condition that affects the way light enters the eye, causing blurred or distorted vision. In this disease, the cornea (front surface of the eye) or the lens inside the eye has an irregular shape, due to which light rays focus on multiple points rather than a single point on the retina. Individuals suffering from the ailment may experience eye strain, fatigue, distorted or tilted vision, eye discomfort, headaches, squinting, trouble seeing at night, difficulty focusing, etc. The diagnosis of astigmatism is typically made through a detailed medical history assessment, a clinical feature evaluation, and an eye examination by an ophthalmologist. The healthcare provider will conduct refraction tests using a phoropter to measure the amount of refractive error in patients. Corneal topography may also be recommended to obtain a comprehensive map of the cornea's curvature that helps to detect any irregularities or abnormalities indicative of the illness. In some cases, additional workups, such as visual acuity tests, keratometry, retinoscopy, etc., are utilized to confirm a diagnosis and rule out other possible causes.

The rising cases of trauma to the eye, such as a penetrating injury, which can alter the shape of the cornea or lens, are primarily driving the astigmatism market. Furthermore, the increasing prevalence of genetic predisposition that results in gene variations, thereby affecting the development of the cornea, lens, and other components of the

eye, is also propelling the market growth. Besides this, the widespread adoption of orthokeratology, since it involves wearing specially designed gas-permeable contact lenses overnight to reshape the cornea and correct astigmatism, is acting as another significant growth-inducing factor. Additionally, the inflating usage of vision therapy, involving a series of exercises and techniques that aim to improve visual skills as well as reduce disease-related symptoms, is further bolstering the market growth. Apart from this, the escalating demand for laser-assisted in situ keratomileusis (LASIK) procedure, owing to its numerous advantages, such as correcting vision problems, providing relatively faster results, and enhancing the quality of life in patients, is expected to drive the astigmatism market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the astigmatism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for astigmatism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the astigmatism market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the astigmatism market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the astigmatism market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current astigmatism marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the astigmatism market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the astigmatism market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the astigmatism market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of astigmatism across the seven major markets?

What is the number of prevalent cases (2018-2034) of astigmatism by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of astigmatism by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with astigmatism across the seven major markets?

What is the size of the astigmatism patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of astigmatism?

What will be the growth rate of patients across the seven major markets?

### Astigmatism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for astigmatism drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the astigmatism market?

What are the key regulatory events related to the astigmatism market?

What is the structure of clinical trial landscape by status related to the astigmatism market?

What is the structure of clinical trial landscape by phase related to the astigmatism market?

What is the structure of clinical trial landscape by route of administration related to the

astigmatism market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 ASTIGMATISM - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 ASTIGMATISM - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 ASTIGMATISM - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 ASTIGMATISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 ASTIGMATISM - UNMET NEEDS**

## **10 ASTIGMATISM - KEY ENDPOINTS OF TREATMENT**

## **11 ASTIGMATISM - MARKETED PRODUCTS**

- 11.1 List of Astigmatism Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 ASTIGMATISM - PIPELINE DRUGS**

### 12.1 List of Astigmatism Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. ASTIGMATISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. ASTIGMATISM – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 ASTIGMATISM - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Astigmatism - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Astigmatism - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Astigmatism - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Astigmatism - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Astigmatism - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
  - 15.4.1 Astigmatism - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Astigmatism - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Astigmatism - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Astigmatism - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Astigmatism - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Astigmatism - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Astigmatism - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Astigmatism - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Astigmatism - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Astigmatism - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Astigmatism - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Astigmatism - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Astigmatism - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Astigmatism - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Astigmatism - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Astigmatism - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Astigmatism - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Astigmatism - Access and Reimbursement Overview

## **16 ASTIGMATISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ASTIGMATISM MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 ASTIGMATISM MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Astigmatism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/AA5ECDD58B6EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA5ECDD58B6EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

